Want to track PHAT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.25 per share versus the Zacks Consensus Estimate of a loss of $1.20. This compares to loss of $0.84 per share a year ago.
Zacks | 2 years ago
Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its products due to the presence of a cancer-causing agent in commercial batches, but eventually received full FDA approval. PHAT aims to target a substantial market opportunity with Vonoprazan, potentially leading to a share price rally and challenging a billion-dollar market cap valuation.
Seekingalpha | 2 years ago
